We are live on ! Find out more
PRAX icon

Praxis Precision Medicines

152 hedge funds and large institutions have $1.31B invested in Praxis Precision Medicines in 2025 Q3 according to their latest regulatory filings, with 28 funds opening new positions, 59 increasing their positions, 45 reducing their positions, and 19 closing their positions.

New
Increased
Maintained
Reduced
Closed

47% more first-time investments, than exits

New positions opened: 28 | Existing positions closed: 19

31% more repeat investments, than reductions

Existing positions increased: 59 | Existing positions reduced: 45

29% more capital invested

Capital invested by funds: $1.02B → $1.31B (+$292M)

20% more call options, than puts

Call options by funds: $27.3M | Put options by funds: $22.7M

6% more funds holding

Funds holding: 143152 (+9)

1.39% less ownership

Funds ownership: 118.57%117.18% (-1.4%)

50% less funds holding in top 10

Funds holding in top 10: 63 (-3)

Holders
152
Holders Change
+9
Holders Change %
+6.29%
% of All Funds
1.99%
Holding in Top 10
3
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-50%
% of All Funds
0.04%
New
28
Increased
59
Reduced
45
Closed
19
Calls
$27.3M
Puts
$22.7M
Net Calls
+$4.62M
Net Calls Change
-$6.17M
Name Holding Trade Value Shares
Change
Change in
Stake
Janus Henderson Group
1
Janus Henderson Group
United Kingdom
$146M +$11.2M +230,454 +9%
Adage Capital Partners
2
Adage Capital Partners
Massachusetts
$126M +$19.4M +399,500 +20%
BlackRock
3
BlackRock
New York
$95.5M +$10.2M +210,952 +13%
PA
4
Perceptive Advisors
New York
$82.9M +$39.4M +811,633 +108%
Point72 Asset Management
5
Point72 Asset Management
Connecticut
$79.3M +$26.3M +541,911 +57%
Vanguard Group
6
Vanguard Group
Pennsylvania
$67.2M +$2.5M +51,642 +4%
T. Rowe Price Associates
7
T. Rowe Price Associates
Maryland
$53.2M -$22.8M -469,585 -32%
CAM
8
Cormorant Asset Management
Massachusetts
$53M -$30.3M -625,000 -38%
State Street
9
State Street
Massachusetts
$48.1M +$10.1M +209,015 +30%
SCM
10
Soleus Capital Management
Connecticut
$45.5M -$5.22M -107,574 -11%
DM
11
Deerfield Management
New York
$44.6M +$7.46M +153,920 +22%
BBA
12
Baker Bros. Advisors
New York
$36.5M
Morgan Stanley
13
Morgan Stanley
New York
$34.1M -$28.3M -582,844 -48%
Goldman Sachs
14
Goldman Sachs
New York
$31.4M +$17.8M +367,029 +162%
DCM
15
Driehaus Capital Management
Illinois
$26.5M -$1.48M -30,437 -6%
Bank of America
16
Bank of America
North Carolina
$25.6M +$1.43M +29,458 +6%
Geode Capital Management
17
Geode Capital Management
Massachusetts
$24.2M +$257K +5,301 +1%
WP
18
Woodline Partners
California
$22.1M +$18M +371,717 +809%
Assenagon Asset Management
19
Assenagon Asset Management
Luxembourg
$21.7M -$9.43M -194,519 -32%
CIBC Asset Management
20
CIBC Asset Management
Ontario, Canada
$20.6M
Franklin Resources
21
Franklin Resources
California
$16.7M +$339 +7 +0%
VC
22
Vivo Capital
California
$10.5M +$1.52M +31,295 +19%
SI
23
Sofinnova Investments
California
$9.16M +$7.62M +157,116 +1,000%
5VM
24
5AM Venture Management
California
$9.01M
Northern Trust
25
Northern Trust
Illinois
$8.92M -$2.2M -45,359 -21%

PRAX Hedge Fund Activity: Q3 2025 in Review

152 of the 7,621 institutional investors tracked by Wall St. Rank reported a position in Praxis Precision Medicines (PRAX) for Q3 2025, worth a combined $1.31B — up 29% from $1.02B a quarter earlier.

Buyers outnumbered sellers: 28 funds opened new PRAX positions and 19 closed out — a net gain of 9 holders — while 59 added to existing stakes and 45 trimmed.

The largest buyer was Perceptive Advisors, adding an estimated $39.4M. The largest seller was Cormorant Asset Management, cutting an estimated $30.3M.

  • 152 institutional investors held Praxis Precision Medicines (PRAX) as of Q3 2025, up from 143 in Q2 2025.
  • Funds reported $1.31B of Praxis Precision Medicines stock for Q3 2025, up 29% quarter-over-quarter.
  • 28 funds opened new Praxis Precision Medicines positions in Q3 2025 and 19 closed out, a net change of +9 holders.
  • The largest Praxis Precision Medicines buyer in Q3 2025 was Perceptive Advisors, an estimated $39.4M added.
  • The largest Praxis Precision Medicines seller in Q3 2025 was Cormorant Asset Management, an estimated $30.3M sold.

Based on aggregated 13F filings for Q3 2025.